Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Immuneering Corp’s stock clocked out at $6.45, down -2.57% from its previous closing price of $6.62. In other words, the price has decreased by -$2.57 from its previous closing price. On the day, 3.3 million shares were traded. IMRX stock price reached its highest trading level at $7.57 during the session, while it also had its lowest trading level at $6.318.
Ratios:
To gain a deeper understanding of IMRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 24.00 and its Current Ratio is at 24.00. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Leerink Partners on October 31, 2025, initiated with a Outperform rating and assigned the stock a target price of $15.
Needham reiterated its Buy rating for the stock on March 15, 2024, while the target price for the stock was revised from $20 to $15.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 03 ’25 when Feinberg Peter bought 7,500 shares for $6.67 per share. The transaction valued at 50,025 led to the insider holds 156,766 shares of the business.
Morales Mallory bought 300 shares of IMRX for $1,917 on Oct 01 ’25. The Chief Accounting Officer now owns 27,533 shares after completing the transaction at $6.39 per share. On Oct 01 ’25, another insider, Neufeld Leah R, who serves as the CHIEF PEOPLE OFFICER of the company, bought 800 shares for $6.38 each. As a result, the insider paid 5,103 and bolstered with 23,344 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMRX now has a Market Capitalization of 407889600 and an Enterprise Value of 211901824.
Stock Price History:
The Beta on a monthly basis for IMRX is 0.47, which has changed by 2.6777778 over the last 52 weeks, in comparison to a change of 0.1476624 over the same period for the S&P500. Over the past 52 weeks, IMRX has reached a high of $10.08, while it has fallen to a 52-week low of $1.10. The 50-Day Moving Average of the stock is -5.76%, while the 200-Day Moving Average is calculated to be 81.69%.
Shares Statistics:
It appears that IMRX traded 1.92M shares on average per day over the past three months and 1255420 shares per day over the past ten days. A total of 63.48M shares are outstanding, with a floating share count of 45.33M. Insiders hold about 26.36% of the company’s shares, while institutions hold 18.18% stake in the company. Shares short for IMRX as of 1761868800 were 7719578 with a Short Ratio of 4.01, compared to 1759190400 on 6278620. Therefore, it implies a Short% of Shares Outstanding of 7719578 and a Short% of Float of 14.099999999999998.
Earnings Estimates
. The current rating of Immuneering Corp (IMRX) is the result of assessments by 6.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.35, with high estimates of -$0.35 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$1.3 and -$1.89 for the fiscal current year, implying an average EPS of -$1.56. EPS for the following year is -$1.84, with 6.0 analysts recommending between -$1.34 and -$2.28.
